PDCD1 and nonpapillary renal cell carcinoma: It is noteworthy that both the INF-α and IL-2 or immune checkpoint inhibitors (ICI) such as PD-1/PD-L1 blockers can significantly improve the overall survival rate (OS) of patients with ccRCC [8].